Literature DB >> 19007587

Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins.

Stella Chun1, Changgui Li, Gary Van Domselaar, Junzhi Wang, Aaron Farnsworth, Xiaoyu Cui, Harold Rode, Terry D Cyr, Runtao He, Xuguang Li.   

Abstract

The fusion peptide is the only universally conserved sequence in the hemagglutinins of all 16 subtypes of influenza A and two genetic lineages of influenza B viruses. Here, peptides selected by bioinformatics approach were modified and conjugated to overcome serious technical hurdles such as the high hydrophobicity and weak immunogenicity of the viral fusion peptides. Antibodies generated against fusion peptides demonstrated remarkable specificity against the viral sequences and robustness of quantitatively analyzing the viral hemagglutinins even under stringent conditions. As quantitatively revealed by antibody-binding experiments, the fusion peptides of diverse hemagglutinins are exposed to the same degree upon unfolding at neutral pH to the physiologically fusogenic state. To our knowledge, this is the first report on the quantitative determination of virtually all influenza vaccines using a single universal antibody.

Mesh:

Substances:

Year:  2008        PMID: 19007587     DOI: 10.1016/j.vaccine.2008.09.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

Review 1.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

2.  Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.

Authors:  Caroline Gravel; Changgui Li; Junzhi Wang; Anwar M Hashem; Bozena Jaentschke; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  J Vis Exp       Date:  2011-04-04       Impact factor: 1.355

3.  Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.

Authors:  Changgui Li; Kangwei Xu; Anwar Hashem; Ming Shao; Shuzhen Liu; Yong Zou; Qiang Gao; Yongchao Zhang; Liyong Yuan; Miao Xu; Xuguang Li; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.

Authors:  Tracey M Doyle; Bozena Jaentschke; Gary Van Domselaar; Anwar M Hashem; Aaron Farnsworth; Nicole E Forbes; Changgui Li; Junzhi Wang; Runtao He; Earl G Brown; Xuguang Li
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

5.  Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Authors:  Surender Khurana; Christopher Larkin; Swati Verma; Manju B Joshi; Juan Fontana; Alasdair C Steven; Lisa R King; Jody Manischewitz; William McCormick; Rajesh K Gupta; Hana Golding
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

6.  A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus.

Authors:  Jenny Aurielle B Babon; John Cruz; Francis A Ennis; Liusong Yin; Masanori Terajima
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

7.  Next Generation Vaccine Biomarkers workshop October 30-31, 2014--Ottawa, Canada.

Authors:  Susan M Twine; Kelly M Fulton; John Spika; Marc Ouellette; Jennifer F Raven; J Wayne Conlan; Lakshmi Krishnan; Luis Barreto; James C Richards
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide.

Authors:  Changgui Li; Bozena Jaentschke; Yingli Song; Junzhi Wang; Terry D Cyr; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  Nat Protoc       Date:  2010-01       Impact factor: 13.491

9.  Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases.

Authors:  Anwar M Hashem; Anathea S Flaman; Aaron Farnsworth; Earl G Brown; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

10.  Development of a novel dual-domain nanoparticle antigen construct for universal influenza vaccine.

Authors:  Yawei Ni; Jianhua Guo; Debra Turner; Ian Tizard
Journal:  Vaccine       Date:  2017-11-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.